Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis

M. C. Park, S. J. Jung, YongBeom Park, S. K. Lee

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives: To determine the serum concentration of tumour necrosis factor (TNF)-related weak inducer of apoptosis (TWEAK) in patients with rheumatoid arthritis (RA) and to investigate the relationship between TWEAK level and disease activity, proinflammatory cytokine levels, and response to anti-TNF treatment. Methods: Serum samples from 40 patients with RA, 40 patients with ankylosing spondylitis (AS), and 40 healthy subjects were collected. Serum samples from 26 patients with RA who received etanercept treatment were also collected in the 12th week of etanercept therapy. Serum TWEAK, TNFα, and interleukin (IL)-6 levels were determined by enzyme-linked immunosorbent assay (ELISA), and disease activity of RA was assessed according to the 28-joint count Disease Activity Score (DAS28). Results: Patients with RA had significantly higher serum levels of TWEAK, TNFα, and IL-6 compared with controls (p<0.05). Patients with AS also had significantly higher serum levels of TNFα and IL-6 (p<0.05), but their serum TWEAK levels were not different from those of the controls. In patients with RA, serum TWEAK levels correlated with DAS28 (r2 = 0.452, p = 0.012) and TNFα levels (r2 = 0.653, p<0.001) but not with IL-6 levels. Among RA patients who were treated with etanercept, responders showed a significant decrease in serum TWEAK levels at the 12th week of treatment, whereas TWEAK levels in nonresponders were not different from their baseline levels. Conclusions: Serum levels of TWEAK were significantly elevated in patients with RA, and reflected disease activity and short-term response to etanercept treatment.

Original languageEnglish
Pages (from-to)173-178
Number of pages6
JournalScandinavian Journal of Rheumatology
Volume37
Issue number3
DOIs
Publication statusPublished - 2008 Jun 30

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Cytokines
Serum
Interleukin-6
Therapeutics
Ankylosing Spondylitis
Joint Diseases
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Apoptosis
Etanercept

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology

Cite this

@article{b8de0703fec44cf3a7ace92d5dafcf61,
title = "Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis",
abstract = "Objectives: To determine the serum concentration of tumour necrosis factor (TNF)-related weak inducer of apoptosis (TWEAK) in patients with rheumatoid arthritis (RA) and to investigate the relationship between TWEAK level and disease activity, proinflammatory cytokine levels, and response to anti-TNF treatment. Methods: Serum samples from 40 patients with RA, 40 patients with ankylosing spondylitis (AS), and 40 healthy subjects were collected. Serum samples from 26 patients with RA who received etanercept treatment were also collected in the 12th week of etanercept therapy. Serum TWEAK, TNFα, and interleukin (IL)-6 levels were determined by enzyme-linked immunosorbent assay (ELISA), and disease activity of RA was assessed according to the 28-joint count Disease Activity Score (DAS28). Results: Patients with RA had significantly higher serum levels of TWEAK, TNFα, and IL-6 compared with controls (p<0.05). Patients with AS also had significantly higher serum levels of TNFα and IL-6 (p<0.05), but their serum TWEAK levels were not different from those of the controls. In patients with RA, serum TWEAK levels correlated with DAS28 (r2 = 0.452, p = 0.012) and TNFα levels (r2 = 0.653, p<0.001) but not with IL-6 levels. Among RA patients who were treated with etanercept, responders showed a significant decrease in serum TWEAK levels at the 12th week of treatment, whereas TWEAK levels in nonresponders were not different from their baseline levels. Conclusions: Serum levels of TWEAK were significantly elevated in patients with RA, and reflected disease activity and short-term response to etanercept treatment.",
author = "Park, {M. C.} and Jung, {S. J.} and YongBeom Park and Lee, {S. K.}",
year = "2008",
month = "6",
day = "30",
doi = "10.1080/03009740801898608",
language = "English",
volume = "37",
pages = "173--178",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Informa Healthcare",
number = "3",

}

Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. / Park, M. C.; Jung, S. J.; Park, YongBeom; Lee, S. K.

In: Scandinavian Journal of Rheumatology, Vol. 37, No. 3, 30.06.2008, p. 173-178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis

AU - Park, M. C.

AU - Jung, S. J.

AU - Park, YongBeom

AU - Lee, S. K.

PY - 2008/6/30

Y1 - 2008/6/30

N2 - Objectives: To determine the serum concentration of tumour necrosis factor (TNF)-related weak inducer of apoptosis (TWEAK) in patients with rheumatoid arthritis (RA) and to investigate the relationship between TWEAK level and disease activity, proinflammatory cytokine levels, and response to anti-TNF treatment. Methods: Serum samples from 40 patients with RA, 40 patients with ankylosing spondylitis (AS), and 40 healthy subjects were collected. Serum samples from 26 patients with RA who received etanercept treatment were also collected in the 12th week of etanercept therapy. Serum TWEAK, TNFα, and interleukin (IL)-6 levels were determined by enzyme-linked immunosorbent assay (ELISA), and disease activity of RA was assessed according to the 28-joint count Disease Activity Score (DAS28). Results: Patients with RA had significantly higher serum levels of TWEAK, TNFα, and IL-6 compared with controls (p<0.05). Patients with AS also had significantly higher serum levels of TNFα and IL-6 (p<0.05), but their serum TWEAK levels were not different from those of the controls. In patients with RA, serum TWEAK levels correlated with DAS28 (r2 = 0.452, p = 0.012) and TNFα levels (r2 = 0.653, p<0.001) but not with IL-6 levels. Among RA patients who were treated with etanercept, responders showed a significant decrease in serum TWEAK levels at the 12th week of treatment, whereas TWEAK levels in nonresponders were not different from their baseline levels. Conclusions: Serum levels of TWEAK were significantly elevated in patients with RA, and reflected disease activity and short-term response to etanercept treatment.

AB - Objectives: To determine the serum concentration of tumour necrosis factor (TNF)-related weak inducer of apoptosis (TWEAK) in patients with rheumatoid arthritis (RA) and to investigate the relationship between TWEAK level and disease activity, proinflammatory cytokine levels, and response to anti-TNF treatment. Methods: Serum samples from 40 patients with RA, 40 patients with ankylosing spondylitis (AS), and 40 healthy subjects were collected. Serum samples from 26 patients with RA who received etanercept treatment were also collected in the 12th week of etanercept therapy. Serum TWEAK, TNFα, and interleukin (IL)-6 levels were determined by enzyme-linked immunosorbent assay (ELISA), and disease activity of RA was assessed according to the 28-joint count Disease Activity Score (DAS28). Results: Patients with RA had significantly higher serum levels of TWEAK, TNFα, and IL-6 compared with controls (p<0.05). Patients with AS also had significantly higher serum levels of TNFα and IL-6 (p<0.05), but their serum TWEAK levels were not different from those of the controls. In patients with RA, serum TWEAK levels correlated with DAS28 (r2 = 0.452, p = 0.012) and TNFα levels (r2 = 0.653, p<0.001) but not with IL-6 levels. Among RA patients who were treated with etanercept, responders showed a significant decrease in serum TWEAK levels at the 12th week of treatment, whereas TWEAK levels in nonresponders were not different from their baseline levels. Conclusions: Serum levels of TWEAK were significantly elevated in patients with RA, and reflected disease activity and short-term response to etanercept treatment.

UR - http://www.scopus.com/inward/record.url?scp=45549101861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549101861&partnerID=8YFLogxK

U2 - 10.1080/03009740801898608

DO - 10.1080/03009740801898608

M3 - Article

VL - 37

SP - 173

EP - 178

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 3

ER -